Security
Biofrontera Inc. Common Stock · BFRI
BFRINASDAQCommon stockCurrentCIK 1858685Updated Nov 14, 2026
BFRI price & chart
Loading TradingView…
NASDAQ:BFRI on TradingView ↗In the news
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 ↗
Recent filings
10-Q filing
SCHEDULE 13G/A - filed by Rosalind Advisors, Inc. regarding Biofrontera Inc.
Results of Operations and Financial Condition
Items 2.02, 9.01
25-NSE - filed by Nasdaq Stock Market LLC regarding Biofrontera Inc.
Other Events
Items 8.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 15,415,000Source | 18,516,000Source | 24,064,000Source | 20,142,000Source | 21,574,000Source | 24,787,000Source | 16,588,000Source | 24,575,000Source | 28,564,000Source | 22,101,000Source | 27,932,000Source | 50,884,000Source |
| Property, Plant and Equipment, NetUSD | 20,000Source | 82,000Source | 2,139,000Source | 37,000Source | 101,000Source | 2,175,000Source | 59,000Source | 120,000Source | 2,158,000Source | 80,000Source | 134,000Source | 204,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 22,000Source | 39,000Source | 2,568,000Source | 26,000Source | 2,448,000Source | 2,609,000Source | 31,000Source | 2,556,000Source | 2,650,000Source | 35,000Source | 2,629,000Source | 3,032,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 3,417,000Source | 2,873,000Source | 4,659,000Source | 7,239,000Source | 4,379,000Source | 6,317,000Source | 1,785,000Source | 3,817,000Source | 6,392,000Source | 5,905,000Source | 1,343,000Source | 17,208,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 2,995,000Source | 4,874,000Source | 5,545,000Source | 3,955,000Source | 3,504,000Source | 3,879,000Source | 4,031,000Source | 3,520,000Source | 7,291,000Source | 5,315,000Source | 5,162,000Source | 3,748,000Source |
| Inventory, NetUSD | 4,329,000Source | 6,526,000Source | 1,097,000Source | 4,028,000Source | 3,946,000Source | 1,231,000Source | 6,527,000Source | 6,905,000Source | 1,426,000Source | 6,646,000Source | 10,908,000Source | 7,168,000Source |
| Assets, CurrentUSD | 14,413,000Source | 16,931,000Source | 12,435,000Source | 18,815,000Source | 17,471,000Source | 13,159,000Source | 15,332,000Source | 20,155,000Source | 18,083,000Source | 20,700,000Source | 23,075,000Source | 43,140,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 629,000Source | 350,000Source | 892,000Source | 331,000Source | 473,000Source | 1,062,000Source | 682,000Source | 560,000Source | 2,279,000Source | 527,000Source | 425,000Source | 810,000Source |
| Operating Lease, Right-of-Use AssetUSD | 488,000Source | 1,081,000Source | 2,813,000Source | 729,000Source | 1,230,000Source | 2,895,000Source | 713,000Source | 1,416,000Source | 1,584,000Source | 903,000Source | 1,612,000Source | 1,375,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 17,996,000Source | 12,986,000Source | 18,108,000Source | 24,810,000Source | 10,663,000Source | 18,717,000Source | 16,119,000Source | 26,421,000Source | 18,084,000Source | 17,668,000Source | 23,139,000Source | 27,006,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 12,000Source | 7,000Source | 14,000Source | 9,000Source | 5,000Source | 12,000Source | 9,000Source | 5,000Source | 12,000Source | 9,000Source | 2,000Source | 1,000Source |
| Additional Paid in CapitalUSD | 130,992,000Source | 121,536,000Source | 139,243,000Source | 122,259,000Source | 121,250,000Source | 138,755,000Source | 122,072,000Source | 104,666,000Source | 138,413,000Source | 121,833,000Source | 104,441,000Source | 103,396,000Source |
| Retained Earnings (Accumulated Deficit)USD | -133,585,000Source | -116,013,000Source | -133,301,000Source | -126,936,000Source | -110,344,000Source | -132,697,000Source | -121,612,000Source | -110,087,000Source | -127,945,000Source | -117,409,000Source | -99,650,000Source | -79,519,000Source |
| Stockholders' Equity Attributable to ParentUSD | -2,581,000Source | 5,530,000Source | 5,956,000Source | -4,668,000Source | 10,911,000Source | 6,070,000Source | 469,000Source | -5,416,000Source | 10,480,000Source | 4,433,000Source | 4,793,000Source | 23,878,000Source |
| Liabilities and EquityUSD | 15,415,000Source | 18,516,000Source | 24,064,000Source | 20,142,000Source | 21,574,000Source | 24,787,000Source | 16,588,000Source | 24,575,000Source | 28,564,000Source | 22,101,000Source | 27,932,000Source | 50,884,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 12,553,000Source | 11,032,000Source | 10,541,000Source | 19,687,000Source | 9,268,000Source | 10,923,000Source | 10,959,000Source | 14,036,000Source | 11,895,000Source | 12,021,000Source | 18,088,000Source | 20,894,000Source |
| Operating Lease, Liability, CurrentUSD | 307,000Source | 670,000Source | 472,000Source | 443,000Source | 701,000Source | 506,000Source | 426,000Source | 690,000Source | 332,000Source | 548,000Source | 691,000Source | 498,000Source |
| Accounts Payable, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 1,278,000Source |
| Operating Lease, Liability, NoncurrentUSD | 136,000Source | 324,000Source | 2,412,000Source | 223,000Source | 443,000Source | 2,499,000Source | 220,000Source | 621,000Source | 1,240,000Source | 276,000Source | 804,000Source | 848,000Source |
| Other Liabilities, NoncurrentUSD | 12,000Source | 29,000Source | 9,000Source | 14,000Source | 31,000Source | 6,000Source | 21,000Source | 33,000Source | 9,000Source | 23,000Source | 37,000Source | 21,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | 4,655,000Source | — | — | 3,593,000Source | 500,000Source | — | 4,230,000Source | — | 4,273,000Source | 4,487,000Source | 10,864,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 55,000Source | 29,000Source | 138,000Source | 600,000Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 342,000Source | 239,000Source | 951,000Source | 1,019,000Source | 1,045,000Source | 1,852,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -3,413,000Source | -1,330,000Source | 1,907,000Source | 315,000Source | 1,536,000Source | 70,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -307,000Source | -119,000Source | -1,445,000Source | -4,233,000Source | 3,750,000Source | 2,810,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -70,000Source | -4,117,000Source | -13,361,000Source | -10,270,000Source | -24,895,000Source | -16,199,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -5,000Source | -3,000Source | 2,998,000Source | -3,000Source | 619,000Source | -5,156,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 5,000Source | 3,000Source | 2,000Source | 10,000Source | 5,000Source | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 10,850,000Source | 14,835,000Source | 8,411,000Source | 14,021,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -75,000Source | -4,120,000Source | 487,000Source | 4,562,000Source | -15,865,000Source | -7,334,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 3,617,000Source | 3,073,000Source | 4,859,000Source | 7,439,000Source | 6,517,000Source | 1,985,000Source | 6,592,000Source | 6,105,000Source | 1,543,000Source | 17,408,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 6,000Source | 1,728,000Source | 125,000Source | 1,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 25,000Source | 24,000Source | 15,000Source | 32,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | 4,000Source | — | 329,000Source | 418,000Source | 418,000Source |
| AssetAcquisitionContingentConsiderationLiabilityUSD | — | — | — | — | — | — | — | — | — | — | — | 2,400,000Source |
| DepreciationUSD | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 100,000Source | 92,000Source | 86,000Source | 101,000Source |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | — | — | — | — | — | — | — | -14,000Source | -7,421,000Source | — |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | 98,000Source | 7,219,000Source | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | -84,000Source | -202,000Source | — |
| Gain (Loss) on InvestmentsUSD | — | — | 1,000Source | -2,000Source | -1,000Source | 2,000Source | — | — | 2,000Source | -14,000Source | -7,421,000Source | 1,747,000Source |
| Gain (Loss) on Sale of Assets and Asset Impairment ChargesUSD | — | — | — | — | — | — | — | — | 700,000Source | — | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | — | 7,385,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | -316,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 5,551,000Source | 3,847,000Source | 4,397,000Source | 6,464,000Source | 5,728,000Source | 4,547,000Source | 22,866,000Source | 16,279,000Source | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | 0Source | 0Source | — | 0Source | 0Source | — | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | 2,000Source | -14,000Source | -7,421,000Source | 1,747,000Source |
| Income Tax Expense (Benefit)USD | — | — | 6,000Source | 3,000Source | 23,000Source | 21,000Source | — | -1,000Source | 25,000Source | 22,000Source | 14,000Source | 32,000Source |
| Inventory Write-downUSD | — | — | — | — | 0Source | — | 100,000Source | — | — | — | — | 100,000Source |
| Investment Income, InterestUSD | — | — | — | 17,000Source | — | — | — | 14,000Source | — | 71,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -6,649,000Source | -5,669,000Source | -604,000Source | -5,324,000Source | -4,752,000Source | -4,203,000Source | -10,536,000Source | -17,759,000Source | -20,131,000Source | -640,000Source |
| Nonoperating Income (Expense)USD | — | — | -365,000Source | -706,000Source | -57,000Source | -224,000Source | -432,000Source | 343,000Source | 837,000Source | -527,000Source | 2,560,000Source | 17,973,000Source |
| Operating ExpensesUSD | — | — | — | 13,972,000Source | 12,527,000Source | 14,109,000Source | 14,404,000Source | 13,135,000Source | 53,053,000Source | — | 56,748,000Source | 47,255,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 30,000Source | -32,000Source | 26,000Source | -264,000Source | -88,000Source | -99,000Source | 388,000Source | 158,000Source | -75,000Source | 33,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Amortization | — | — | — | — | —Source | — | — | — | — | — | — | — |
| InterestExpenseNonoperating | — | — | — | — | — | — | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 6,988,000Source | 9,012,000Source | 12,003,000Source | 9,030,000Source | 10,084,000Source | 8,588,000Source | 41,705,000Source | 37,321,000Source | 34,071,000Source | 28,541,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 10,047,000Source | 8,425,000Source | 9,628,000Source | 10,528,000Source | 10,994,000Source | 8,653,000Source | 37,751,000Source | — | 38,975,000Source | 35,137,000Source |
| Operating Income (Loss)USD | — | — | -6,278,000Source | -4,960,000Source | -524,000Source | -5,079,000Source | -4,320,000Source | -4,547,000Source | -11,348,000Source | -17,210,000Source | -22,677,000Source | -18,581,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 30,000Source | -32,000Source | 26,000Source | -264,000Source | -88,000Source | -99,000Source | 388,000Source | 158,000Source | -75,000Source | 33,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -6,643,000Source | -5,666,000Source | -581,000Source | -5,303,000Source | -4,752,000Source | -4,204,000Source | -10,511,000Source | -17,737,000Source | -20,117,000Source | -608,000Source |
| Income Tax Expense (Benefit)USD | — | — | 6,000Source | 3,000Source | 23,000Source | 21,000Source | — | -1,000Source | 25,000Source | 22,000Source | 14,000Source | 32,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -6,649,000Source | -5,669,000Source | -604,000Source | -5,324,000Source | -4,752,000Source | -4,203,000Source | -10,536,000Source | -17,759,000Source | -20,131,000Source | -640,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.62Source | -0.98Source | -0.05Source | -0.57Source | -0.41Source | -0.47Source | -1.04Source | -3.22Source | -13.02Source | -0.61Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.62Source | -0.98Source | -0.05Source | -0.57Source | -0.41Source | -0.47Source | -1.04Source | -3.22Source | -13.02Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 10,776,739Source | 5,773,993Source | 12,923,710Source | 9,351,557Source | 11,683,323Source | 8,873,932Source | 10,171,921Source | 5,516,334Source | 1,546,297Source | 1,056,988Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 10,776,739Source | 5,773,993Source | 12,923,710Source | 9,351,557Source | 11,683,323Source | 8,873,932Source | 10,171,921Source | 5,516,334Source | 1,546,297Source | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | 4,000Source | — | 329,000Source | 418,000Source | 418,000Source |
| Costs and ExpensesUSD | — | — | 13,266,000Source | 13,972,000Source | 12,527,000Source | 14,109,000Source | 14,404,000Source | 13,135,000Source | 53,053,000Source | 54,531,000Source | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | — | 600,000Source | — | — |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | 98,000Source | 7,219,000Source | — |
| Gain (Loss) on InvestmentsUSD | — | — | 1,000Source | -2,000Source | -1,000Source | 2,000Source | — | — | 2,000Source | -14,000Source | -7,421,000Source | 1,747,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | — | 7,385,000Source | — |
| General and Administrative ExpenseUSD | — | — | 5,551,000Source | 3,847,000Source | 4,397,000Source | 6,464,000Source | 5,728,000Source | 4,547,000Source | 22,866,000Source | 16,279,000Source | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | 2,000Source | -14,000Source | -7,421,000Source | 1,747,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 220,000Source | 195,000Source |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | -468,000Source | -195,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | -111,000Source | 8,000Source | -126,000Source | -115,000Source | -125,000Source | -106,000Source | -452,000Source | -2,035,000Source | — | — |
| Interest Income, OtherUSD | — | — | — | — | — | — | — | — | — | — | 132,000Source | 10,000Source |
| Investment Income, InterestUSD | — | — | — | 17,000Source | — | — | — | 14,000Source | — | 71,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | -365,000Source | -706,000Source | -57,000Source | -224,000Source | -432,000Source | 343,000Source | 837,000Source | -527,000Source | 2,560,000Source | 17,973,000Source |
| Operating ExpensesUSD | — | — | — | 13,972,000Source | 12,527,000Source | 14,109,000Source | 14,404,000Source | 13,135,000Source | 53,053,000Source | — | 56,748,000Source | 47,255,000Source |
| Research and Development ExpenseUSD | — | — | 854,000Source | 669,000Source | 448,000Source | 870,000Source | 900,000Source | 1,207,000Source | 3,719,000Source | 2,089,000Source | 77,000Source | — |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Interest Expense (non-operating) | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Other General Expense | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
Filing attachments
ex99-1.htm · 8-K · 2026-11-13
Exhibit 99.1 Biofrontera Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue Growth WOBURN, Mass., November 13, 2026 - Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the quarter ended September 30, 2026. Third Quarter 2026 Highlights Net product revenue of $9.1 mill…
Read attachment ↗ex99-1.htm · 8-K · 2026-09-14
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera’s photodynamic therapy platform WOBURN, Mass., September 14, 2026 - Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Comp…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth WOBURN, Mass., August 13, 2026 - Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the quarter ended June 30, 2026. Second Quarter 2026 Highlights Net product revenue…
Read attachment ↗ex107.htm · S-8 · 2026-07-22
Calculation of Filing Fee Tables S-8 Biofrontera Inc. ──────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee ────────────────────────────────…
Read attachment ↗ex4-7.htm · S-8 · 2026-07-22
EXHIBIT 4.7 Biofrontera Inc. AMENDED AND RESTATED 2021 OMNIBUS INCENTIVE PLAN 1. Purpose The purpose of the Plan is to provide a means through which the Company and its Affiliates may attract able persons to enter and remain in the employ of the Company and its Affiliates and to provide a means whereby employees, directors and consultants of the Company and its Affiliates can acquire and maintain Common Stock ownership, or be paid incentive compensation measured by reference to the value of…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-14
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update Woburn, MA (May 14, 2026) (GLOBE NEWSWIRE) - Biofrontera Inc. (NASDAQ: BFRI) (the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three months ended March 31, 2026 and provided a business update. First Quarter Financial Highl…
Read attachment ↗